Compare REGN & EQIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | EQIX |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3B | 103.1B |
| IPO Year | 1995 | 2000 |
| Metric | REGN | EQIX |
|---|---|---|
| Price | $919.82 | $971.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 35 |
| Target Price | $991.00 | ★ $1,234.88 |
| AVG Volume (30 Days) | ★ 869.8K | 610.3K |
| Earning Date | 10-30-2026 | 10-28-2026 |
| Dividend Yield | 0.41% | ★ 2.03% |
| EPS Growth | 8.19 | ★ 61.88 |
| EPS | ★ 37.37 | 13.96 |
| Revenue | $5,872,227,000.00 | ★ $5,998,545,000.00 |
| Revenue This Year | $31.18 | $11.77 |
| Revenue Next Year | $7.19 | $11.35 |
| P/E Ratio | ★ $24.71 | $72.93 |
| Revenue Growth | ★ 20.82 | 7.85 |
| 52 Week Low | $591.52 | $720.62 |
| 52 Week High | $991.73 | $1,128.68 |
| Indicator | REGN | EQIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 39.63 |
| Support Level | $735.26 | $930.35 |
| Resistance Level | $986.64 | $984.17 |
| Average True Range (ATR) | 32.57 | 33.74 |
| MACD | -4.43 | -4.65 |
| Stochastic Oscillator | 32.58 | 3.38 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).